Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.
- DOI
- 10.1080/14796694.2024.2402680
- Published
- 2024
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2024.2402680,
title = {Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.},
author = {Atallah EL and Mauro MJ and Sasaki K and Levy MY and Koller P and Yang D and Laine D and Sabo J and Gu E and Cortes JE},
year = {2024},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2024.2402680},
url = {https://doi.org/10.1080/14796694.2024.2402680}
}RIS
TY - JOUR TI - Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. AU - Atallah EL AU - Mauro MJ AU - Sasaki K AU - Levy MY AU - Koller P AU - Yang D AU - Laine D AU - Sabo J AU - Gu E AU - Cortes JE PY - 2024 JO - Future oncology (London, England) DO - 10.1080/14796694.2024.2402680 UR - https://doi.org/10.1080/14796694.2024.2402680 ER -
APA
EL, A., MJ, M., K, S., MY, L., P, K., D, Y., D, L., J, S., E, G., & JE, C. (2024). Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.. Future oncology (London, England). https://doi.org/10.1080/14796694.2024.2402680
Source records
- pubmed · retrieved 2026-09-26T05:48:44.470Z
- europe-pmc · retrieved 2026-09-26T05:48:44.481Z